Effect of additional aprepitant on palonosetron and dexamethasone for prevention of moderately emetogenic chemotherapy-induced nausea and vomiting in patients with lung cancer: clinical phase II study
Phase 2
Recruiting
- Conditions
- lung cancer
- Registration Number
- JPRN-UMIN000008318
- Lead Sponsor
- Dokkyo Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1)vomiting within 24h before first chemotherapy 2)continuatory use of severely or moderately emetogenic anticancer drugs after Day 2 3)concurrent radiotherapy 4) Severe complications 5)Symptomatic brain meta 6)Hypersensitivity for PaIonosetron, Aprepitant, Dexamethasone 7) Other patients who are unfit for the study as determined by the attending physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Complete Response (CR) rate
- Secondary Outcome Measures
Name Time Method